Which has stronger earnings and valuation, FTH or PEPG?

PepGen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is FTH or PEPG more profitable?

PepGen's return on equity of -59.89% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% PepGen N/A -59.89% -49.62%

Which has preferable valuation & earnings, AARD or FTH?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is AARD or FTH more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -61.71% -56.29% Sensei Biotherapeutics N/A -83.59% -256.50%

Which has better earnings & valuation, FTH or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A Polaryx Therapeutics N/A N/A N/A -$0.05 N/A

Is FTH or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Polaryx Therapeutics N/A N/A N/A

Which has better earnings & valuation, CRDL or FTH?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is CRDL or FTH more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Sensei Biotherapeutics N/A -83.59% -256.50%

Which has higher earnings and valuation, PMN or FTH?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is PMN or FTH more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media refer more to PMN or FTH?

In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 1 mentions for Promis Neurosciences. Sensei Biotherapeutics' average media sentiment score of 1.38 beat Promis Neurosciences' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sensei Biotherapeutics (FTH) Competitors

$28.02 +1.91 (+7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$27.20 -0.82 (-2.94%)

As of 04:19 PM Eastern

Compare

FTH vs. PEPG, AARD, PLYX, CRDL, and PMN

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include PepGen (PEPG), Aardvark Therapeutics (AARD), Polaryx Therapeutics (PLYX), Cardiol Therapeutics (CRDL), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to PepGen?

Sensei Biotherapeutics (NASDAQ:FTH) and PepGen (NASDAQ:PEPG) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Sensei Biotherapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, PepGen has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PepGen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Sensei Biotherapeutics currently has a consensus target price of $58.50, suggesting a potential upside of 108.78%. PepGen has a consensus target price of $11.50, suggesting a potential upside of 477.89%. Given PepGen's higher probable upside, analysts clearly believe PepGen is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than PepGen. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for PepGen. Sensei Biotherapeutics' average media sentiment score of 1.38 beat PepGen's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Positive
PepGen	Neutral

PepGen's return on equity of -59.89% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
PepGen	N/A	-59.89%	-49.62%

Summary

Sensei Biotherapeutics and PepGen tied by winning 7 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Aardvark Therapeutics currently has a consensus target price of $19.70, indicating a potential upside of 273.11%. Sensei Biotherapeutics has a consensus target price of $58.50, indicating a potential upside of 108.78%. Given Aardvark Therapeutics' higher possible upside, research analysts plainly believe Aardvark Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Sensei Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Aardvark Therapeutics has a beta of 3.93, suggesting that its share price is 293% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for Aardvark Therapeutics. Sensei Biotherapeutics' average media sentiment score of 1.38 beat Aardvark Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Sensei Biotherapeutics	Positive

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aardvark Therapeutics' return on equity of -61.71% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Summary

Sensei Biotherapeutics beats Aardvark Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Polaryx Therapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Polaryx Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sensei Biotherapeutics presently has a consensus price target of $58.50, indicating a potential upside of 108.78%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 292.16%. Given Polaryx Therapeutics' higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for Polaryx Therapeutics. Sensei Biotherapeutics' average media sentiment score of 1.38 beat Polaryx Therapeutics' score of 0.68 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Positive
Polaryx Therapeutics	Positive

Summary

Sensei Biotherapeutics beats Polaryx Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for Cardiol Therapeutics. Sensei Biotherapeutics' average media sentiment score of 1.38 beat Cardiol Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Sensei Biotherapeutics	Positive

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Sensei Biotherapeutics' return on equity of -83.59% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Cardiol Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 750.00%. Sensei Biotherapeutics has a consensus target price of $58.50, suggesting a potential upside of 108.78%. Given Cardiol Therapeutics' higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sensei Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Sensei Biotherapeutics beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Promis Neurosciences presently has a consensus price target of $24.00, suggesting a potential upside of 74.17%. Sensei Biotherapeutics has a consensus price target of $58.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Sensei Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 1 mentions for Promis Neurosciences. Sensei Biotherapeutics' average media sentiment score of 1.38 beat Promis Neurosciences' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics' return on equity of -83.59% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Promis Neurosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Promis Neurosciences has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Sensei Biotherapeutics beats Promis Neurosciences on 9 of the 14 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTH vs. The Competition

Export

Metric	Sensei Biotherapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$37.55M	$955.68M	$4.41B	$12.46B
Dividend Yield	N/A	4.84%	16.12%	6.49%
P/E Ratio	-0.20	1.60	23.83	24.29
Price / Sales	N/A	118.37	154.63	115.92
Price / Cash	N/A	20.06	34.70	57.41
Price / Book	1.90	8.34	13.63	6.38
Net Income	-$21.08M	-$4.99M	$116.30M	$331.30M
7 Day Performance	18.43%	-1.53%	-1.73%	-1.82%
1 Month Performance	N/A	3.02%	-0.77%	0.86%
1 Year Performance	N/A	49.31%	9.44%	22.16%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTH Sensei Biotherapeutics	4.446 of 5 stars	$28.02 +7.3%	$58.50 +108.8%	N/A	$37.55M	N/A	N/A	40	Positive News
PEPG PepGen	2.564 of 5 stars	$1.81 +0.6%	$11.50 +535.4%	+84.7%	$125.20M	N/A	N/A	30
AARD Aardvark Therapeutics	3.3722 of 5 stars	$5.62 -2.4%	$19.70 +250.5%	-60.9%	$122.63M	N/A	N/A	18
PLYX Polaryx Therapeutics	2.0018 of 5 stars	$2.58 -3.0%	$10.00 +287.6%	N/A	$121.34M	N/A	N/A	11	News Coverage Positive News
CRDL Cardiol Therapeutics	1.4419 of 5 stars	$1.05 -0.9%	$8.50 +709.5%	-30.3%	$121.01M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTH) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Competitors

FTH vs. PEPG, AARD, PLYX, CRDL, and PMN

How does Sensei Biotherapeutics compare to PepGen?

Summary

How does Sensei Biotherapeutics compare to Aardvark Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Polaryx Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Cardiol Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Competitors

FTH vs. PEPG, AARD, PLYX, CRDL, and PMN

How does Sensei Biotherapeutics compare to PepGen?

Which has more volatility & risk, FTH or PEPG?

Do insiders & institutionals hold more shares of FTH or PEPG?

Which has stronger earnings and valuation, FTH or PEPG?

Do analysts prefer FTH or PEPG?

Does the media prefer FTH or PEPG?

Is FTH or PEPG more profitable?

Summary

How does Sensei Biotherapeutics compare to Aardvark Therapeutics?

Do analysts rate AARD or FTH?

Which has preferable valuation & earnings, AARD or FTH?

Which has more volatility and risk, AARD or FTH?

Does the media refer more to AARD or FTH?

Do insiders and institutionals believe in AARD or FTH?

Is AARD or FTH more profitable?

Summary

How does Sensei Biotherapeutics compare to Polaryx Therapeutics?

Is FTH or PLYX more profitable?

Which has better earnings & valuation, FTH or PLYX?

Do insiders & institutionals believe in FTH or PLYX?

Do analysts recommend FTH or PLYX?

Does the media favor FTH or PLYX?

Summary

How does Sensei Biotherapeutics compare to Cardiol Therapeutics?

Which has better earnings & valuation, CRDL or FTH?

Does the media refer more to CRDL or FTH?

Do institutionals and insiders have more ownership in CRDL or FTH?

Which has more risk and volatility, CRDL or FTH?

Is CRDL or FTH more profitable?

Do analysts rate CRDL or FTH?

Summary

How does Sensei Biotherapeutics compare to Promis Neurosciences?

Do analysts rate PMN or FTH?

Does the media refer more to PMN or FTH?

Is PMN or FTH more profitable?

Which has higher earnings and valuation, PMN or FTH?

Which has more volatility and risk, PMN or FTH?

Do insiders and institutionals have more ownership in PMN or FTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools